These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18692684

  • 1. Deregulation of signaling pathways in acute myeloid leukemia.
    Scholl C, Gilliland DG, Fröhling S.
    Semin Oncol; 2008 Aug; 35(4):336-45. PubMed ID: 18692684
    [Abstract] [Full Text] [Related]

  • 2. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
    Doepfner KT, Boller D, Arcaro A.
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
    [Abstract] [Full Text] [Related]

  • 3. Molecularly targeted therapy in acute myeloid leukemia.
    Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Quarna J.
    Ann N Y Acad Sci; 2004 Dec; 1028():409-22. PubMed ID: 15650266
    [Abstract] [Full Text] [Related]

  • 4. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M, Rönnstrand L, Sun J.
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [Abstract] [Full Text] [Related]

  • 5. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).
    Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, List AF.
    Leuk Res; 2008 Jun; 32(6):893-903. PubMed ID: 18179820
    [Abstract] [Full Text] [Related]

  • 6. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N, Auewarakul CU.
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [Abstract] [Full Text] [Related]

  • 7. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
    Usher SG, Radford AD, Villiers EJ, Blackwood L.
    Exp Hematol; 2009 Jan; 37(1):65-77. PubMed ID: 18977066
    [Abstract] [Full Text] [Related]

  • 8. The molecular pathogenesis of acute myeloid leukemia.
    Steffen B, Müller-Tidow C, Schwäble J, Berdel WE, Serve H.
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):195-221. PubMed ID: 16236521
    [Abstract] [Full Text] [Related]

  • 9. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
    McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM.
    Leukemia; 2008 Apr; 22(4):708-22. PubMed ID: 18337766
    [Abstract] [Full Text] [Related]

  • 10. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E, Graham C, Corrigan PM, Thomas KG, Freeburn RW, Wheadon H.
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [Abstract] [Full Text] [Related]

  • 11. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.
    Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Böhmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Müller-Tidow C, Mann M, Serve H.
    Mol Cell; 2009 Oct 23; 36(2):326-39. PubMed ID: 19854140
    [Abstract] [Full Text] [Related]

  • 12. Dominant and opportunistic leukemic clones: proposal for a pathogenesis-oriented classification in acute myeloid leukemia.
    Cucuianu A.
    Med Hypotheses; 2005 Oct 23; 65(1):107-13. PubMed ID: 15893127
    [Abstract] [Full Text] [Related]

  • 13. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y, Harada H.
    J Cell Physiol; 2009 Jul 23; 220(1):16-20. PubMed ID: 19334039
    [Abstract] [Full Text] [Related]

  • 14. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL, Dedhar S, Hogge DE.
    Exp Hematol; 2009 Apr 23; 37(4):450-60. PubMed ID: 19302919
    [Abstract] [Full Text] [Related]

  • 15. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 16. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
    Masson K, Liu T, Khan R, Sun J, Rönnstrand L.
    Br J Haematol; 2009 Jul 15; 146(2):193-202. PubMed ID: 19438505
    [Abstract] [Full Text] [Related]

  • 17. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
    Piazza F, Semenzato G.
    Expert Rev Anticancer Ther; 2004 Jun 15; 4(3):387-400. PubMed ID: 15161438
    [Abstract] [Full Text] [Related]

  • 18. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T.
    Eur J Haematol; 2009 Aug 15; 83(2):90-8. PubMed ID: 19309322
    [Abstract] [Full Text] [Related]

  • 19. Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4.
    Tickenbrock L, Hehn S, Sargin B, Choudhary C, Bäumer N, Buerger H, Schulte B, Müller O, Berdel WE, Müller-Tidow C, Serve H.
    Int J Oncol; 2008 Dec 15; 33(6):1215-21. PubMed ID: 19020754
    [Abstract] [Full Text] [Related]

  • 20. Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.
    Cammenga J.
    Leukemia; 2005 Oct 15; 19(10):1719-28. PubMed ID: 16107893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.